Carregant...

Amplifying TLR-MyD88 signals within tumor-specific T-cells enhances antitumor activity to suboptimal levels of weakly-immunogenic tumor-antigens

The efficacy of T-cell–based immunotherapy to treat cancer patients remains a challenge partly because of the weak activity toward subdominant tumor-antigens (TAg) and to tumors expressing suboptimal TAg levels. Recent reports indicate that Toll-like receptor (TLR) stimulation on T-cells can lower t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Geng, Degui, Zheng, Liqin, Srivastava, Ratika, Velasco-Gonzalez, Cruz, Riker, Adam, Markovic, Svetomir N., Davila, Eduardo
Format: Artigo
Idioma:Inglês
Publicat: 2010
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3463001/
https://ncbi.nlm.nih.gov/pubmed/20807806
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-10-0247
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!